192 related articles for article (PubMed ID: 23984807)
21. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
Sawhney R; Kabbinavar F
Curr Urol Rep; 2008 Jan; 9(1):26-33. PubMed ID: 18366971
[TBL] [Abstract][Full Text] [Related]
23. Ascofuranone suppresses EGF-induced HIF-1α protein synthesis by inhibition of the Akt/mTOR/p70S6K pathway in MDA-MB-231 breast cancer cells.
Jeong YJ; Cho HJ; Magae J; Lee IK; Park KG; Chang YC
Toxicol Appl Pharmacol; 2013 Dec; 273(3):542-50. PubMed ID: 24096035
[TBL] [Abstract][Full Text] [Related]
24. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development.
Rasmussen N; Rathmell WK
Curr Clin Pharmacol; 2011 Aug; 6(3):199-206. PubMed ID: 21470103
[TBL] [Abstract][Full Text] [Related]
25. Development of c-MET pathway inhibitors.
Liu X; Newton RC; Scherle PA
Expert Opin Investig Drugs; 2011 Sep; 20(9):1225-41. PubMed ID: 21740293
[TBL] [Abstract][Full Text] [Related]
26. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
Saylor PJ; Escudier B; Michaelson MD
Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
[TBL] [Abstract][Full Text] [Related]
27. Anti-angiogenic therapy in renal cell carcinoma.
Sharma SG; Nanda S; Longo S
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):77-83. PubMed ID: 19601920
[TBL] [Abstract][Full Text] [Related]
28. Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.
Felici A; Bria E; Tortora G; Cognetti F; Milella M
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1545-57. PubMed ID: 23253221
[TBL] [Abstract][Full Text] [Related]
29. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
30. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
31. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.
Santoni M; Berardi R; Amantini C; Burattini L; Santini D; Santoni G; Cascinu S
Int J Cancer; 2014 Jun; 134(12):2772-7. PubMed ID: 24114790
[TBL] [Abstract][Full Text] [Related]
32. From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer.
Chung C
Am J Health Syst Pharm; 2020 Dec; 77(24):2064-2073. PubMed ID: 33016992
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
34. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
Choueiri TK; Bukowski RM; Rini BI
Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
[TBL] [Abstract][Full Text] [Related]
35. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
36. Non-clear cell advanced kidney cancer: is there a gold standard?
Sánchez P; Calvo E; Durán I
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
[TBL] [Abstract][Full Text] [Related]
37. Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.
Reuter CW; Morgan MA; Grünwald V; Herrmann TR; Burchardt M; Ganser A
World J Urol; 2007 Mar; 25(1):59-72. PubMed ID: 17340158
[TBL] [Abstract][Full Text] [Related]
38. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
Roulin D; Demartines N; Dormond O
Biochem Soc Trans; 2011 Apr; 39(2):492-4. PubMed ID: 21428926
[TBL] [Abstract][Full Text] [Related]
39. Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma.
Rodríguez-Antona C; García-Donas J
Pharmacogenomics; 2012 Nov; 13(14):1621-33. PubMed ID: 23148638
[TBL] [Abstract][Full Text] [Related]
40. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]